At BioCrea we turn concepts into drug candidates, creating first-in-class drugs to treat debilitating central nervous system (CNS) diseases. Through the combination of our unique discovery platforms, the use of patient-derived models and clinical data together with an experienced, visionary team, the company discovers and develops new drug candidates for pharmaceutical and biotechnology partners.
October 30, 2013
BIO-Europe to be held November 4-6 in Vienna, Austria
October 07, 2013
BIO Investor Forum to be held October 8-9 in San Francisco, USA
September 09, 2013
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialists validated through pharma partnerships, is now a member of the international Biotechnology Industry Organization (BIO).